| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000031240 |
| Receipt No. | R000035463 |
| Official scientific title of the study | Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probe |
| Date of disclosure of the study information | 2018/02/09 |
| Last modified on | 2018/02/09 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probe | |
| Title of the study (Brief title) | Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probe | |
| Region |
|
|
| Condition | ||
| Condition | Breast cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is, using super paramagnetic iron oxide (SPIO)/magnetic probe system model, to demonstrate non-inferiority of SPIO/magnetic probe system compared with an isotope technique for SNB in patients with breast cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Identification rate |
| Key secondary outcomes | Safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Self control |
| Stratification | NO |
| Dynamic allocation | |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | On the day before surgery or in the morning of the operation day, 1ml a superparamagnetic iron oxide (SPIO) contrast agent are injected on the same side of breast cancer in subcutaneous areola. All sentinel lymph nodes detected intraoperatively by using the magnetic probe system model or gamma probe or nodes that were blue or brown, were excised. Sentinel lymph nodes are evaluated the status of node metastasis and iron-staining. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Primary breast cancer with clinical no lymph node metastasis | |||
| Key exclusion criteria | 1. Breast cancer recurrence
2. Who had a history of operation of Axilla 3. Post operative status of augmentation mammaplasty 4. Male breast cancer |
|||
| Target sample size | 180 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Takei |
| Organization | Nippon Medical School Hospital |
| Division name | Department of Breast Surgery |
| Address | 1-1-5 Sendagi, Bunkyo-ku, Tokyo |
| TEL | 03-3822-2131 |
| takei-hiroyuki@nms.ac.jp | |
| Public contact | |
| Name of contact person | Tomoko Kurita |
| Organization | Nippon Medical School Hospital |
| Division name | Department of Breast Surgery |
| Address | 1-1-5 Sendagi, Bunkyo-ku, Tokyo |
| TEL | 03-3822-2131 |
| Homepage URL | |
| tomoko28@nms.ac.jp | |
| Sponsor | |
| Institute | Japan Agency for Medical Research and Development |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Agency for Medical Research and Development |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Nippon Medical School
Showa University |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 日本医科大学(東京都)、昭和大学(東京都)
|
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035463 |